WBC | 20.2 | 14.5 | 9.6 | 6.5 | 8.6 | 9.0 | 4.5–11 X 103/uL |
RBC | 2.48* | 2.18 | 2.44 | 2.53 | 2.64 | 2.86 | 4.0–5.4 X 106/uL |
HGB | 7.6* | 6.5 | 7.5 | 8.2 | 8.5 | 9.2 | 12.0–16.0 g/dL |
HCT | 24.0* | 19.6 | 23.2 | 26.2 | 27.9 | 29.6 | 36.0%–47.0% |
PLT | 46* | 52 | 121 | 143 | 156 | 186 | 150–450 X 103/uL |
DIFF | ↑ PMN* | ↑ PMN | ↑ PMN1 meta, 1 myelo | | | | |
RBC morphology | 1+ poly1+ decryoOcc. Shisto* | 2+ aniso1+ polyOcc. Shisto | 2+ aniso1+ polyOcc. Shisto | 3+ aniso1+ macro1+ stomato1+ decryoOcc. Shisto | 3+ aniso1+ macroOcc. Shisto | | |
INR | 0.9§ | 1.3 | 1.3 | | | | 1.0 |
APTT | 23.5§ | 33.2 | 33.2 | | | | 25.1–36.5 s |
FIB | 229† | 292 | 635 | | | | 200–400 mg/dL |
FDP | >5, <20† | | | | | | <5 ug/mL |
SUN | 31* | 69 | 20 | 29 | 9 | 20 | 7–18 mg/dL |
CR | 1.9* | 3.5 | 2.6 | 7.2 | 4.2 | 6.5 | 0.6–1.3 mg/dL |
ALT | 79* | 28 | 19 | 13 | 12 | | 13–56 U/L |
AST | 257* | 59 | 28 | 22 | 23 | | 15–37 U/L |
LDH | 746* | | 778 | 439 | 414 | | 84–246 U/L |
CK-MB | | Low MI probability | | No evidence of acute MI | | | |
Troponin I | | Low MI probability | | Developing or subclinical MI | | | |
BNP | | | 991 | | 2744 | | <125 pg.mL |
C3 | | 107.0‖ | | 84.4 | | | 90–180 mg/dL |
C4 | | 25.7‖ | | 11.4 | | | 10–40 mg/dL |
Haptoglobin | | | 8 | | | | 40–240 mg/dL |
Shiga Toxin I | | Neg‡ | | | | | Negative |
Shiga Toxin 2 | | Neg‡ | | | | | Negative |
Cl. Diff. | | Neg | | | | | Negative |
ADAMTS13 | | 20# | | | | | >60% |
Renal biopsy | | | Changes consistent with toxemia of pregnancy with progression to frank TMA. Given history of recent pregnancy, this most likely represents HELLP syndrome. However, HUS, aHUS, and TTP cannot be excluded. |